Author

M. Merchant

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

J. Oeh· 2 shared A. Bera· 1 shared A. Dey· 1 shared A. Olivero· 1 shared A. Ranjan· 1 shared A. Shah· 1 shared B. Oudit· 1 shared B. Tran· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

J. Oeh

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib

Y. Pang, Q. Li, Z. Sergi, G. Yu, X. Sang, O. Kim, H. Wang, A. Ranjan, M. Merchant, B. Oudit, R. W. Robey, F. Soheilian, B. Tran, F. J. Nunez, M. Zhang, , J. Wu

This paper identifies zotiraciclib as a therapeutic agent targeting IDH-mutant gliomas by disrupting mitochondrial function and inducing oxidative stress, leading to a clinical trial.

bioRxiv · Jun 29, 2023Cancer Biology

Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunity

R. Barreira da Silva, R. Leitao, X. Pechuan, S. Werneke, J. Oeh, V. Javinal, Y. Wang, W. Phung, C. Everett, J. Nonomiya, D. Arnott, C. Lu, Y.-C. Hsiao, J. T. Koerber, I. Hotzel, , M. Albert

This study shows that QPCTL inhibition reduces monocyte migration and alters myeloid cell infiltration, enhancing anti-tumor immunity when combined with anti-PD-L1 therapy.

bioRxiv · Jan 25, 2022Immunology

MK2 Expression Promotes Non-Small Cell Lung Cancer Cell Death and Predicts Survival

O. Del Rosario, K. Suresh, M. Kallem, G. Singh, A. Shah, Y. Xin, N. Philip, F. D'Alessio, M. Srivastava, A. Bera, L. Shimoda, M. Merchant, M. Rane, C. Machamer, J. Mock, , M. Damarla

This study shows MK2 promotes apoptosis in non-small cell lung cancer by facilitating caspase 3 nuclear translocation, and higher MK2 expression correlates with better patient survival.

bioRxiv · Nov 30, 2021 · PreprintCancer Biology

RTK-dependent inducible degradation of mutant PI3K alpha drives GDC-0077 (Inavolisib) efficacy

K. Song, K. Edgar, E. Hanan, M. Hafner, J. Oeh, M. Merchant, D. Sampath, M. Nannini, R. Hong, L. Phu, W. Forrest, E. Stawiski, S. schmidt, N. Endres, J. Guan, , L. Friedman

The paper shows that GDC-0077 and taselisib degrade mutant PI3K alpha via HER2-dependent mechanisms, enhancing efficacy in PIK3CA-mutant breast cancer.

bioRxiv · May 12, 2021Cancer Biology